Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Rudolf Hess - The Doppelgänger conspiracy theory disproved.

McCall S, Kreindl G, Kastinger T, Müller E, Zahrer W, Grießner I, Dunkelmann B, Tutsch-Bauer E, Neuhuber F, Pittman PR, Wahl R, Lowry M, Cemper-Kiesslich J.

Forensic Sci Int Genet. 2019 May;40:18-22. doi: 10.1016/j.fsigen.2019.01.004. Epub 2019 Jan 11.

PMID:
30685710
2.

Human transcriptome response to immunization with live-attenuated Venezuelan equine encephalitis virus vaccine (TC-83): Analysis of whole blood.

Erwin-Cohen RA, Porter AI, Pittman PR, Rossi CA, DaSilva L.

Hum Vaccin Immunother. 2017 Jan 2;13(1):169-179. doi: 10.1080/21645515.2016.1227900. Epub 2016 Nov 21.

3.

Povidone Iodine Ointment Application to the Vaccination Site Does Not Alter Immunoglobulin G Antibody Response to Smallpox Vaccine.

Pugh C, Brown ES, Quinn X, Korman L, Dyas BK, Ulrich RG, Pittman PR.

Viral Immunol. 2016 Jul-Aug;29(6):361-6. doi: 10.1089/vim.2016.0025. Epub 2016 May 23.

PMID:
27214505
4.

Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans.

Pittman PR, McClain D, Quinn X, Coonan KM, Mangiafico J, Makuch RS, Morrill J, Peters CJ.

Vaccine. 2016 Jan 20;34(4):424-429. doi: 10.1016/j.vaccine.2015.12.030. Epub 2015 Dec 22.

PMID:
26718688
5.

Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.

Pittman PR, Norris SL, Brown ES, Ranadive MV, Schibly BA, Bettinger GE, Lokugamage N, Korman L, Morrill JC, Peters CJ.

Vaccine. 2016 Jan 20;34(4):523-530. doi: 10.1016/j.vaccine.2015.11.078. Epub 2015 Dec 17.

6.

Safety and immunogenicity of ricin vaccine, RVEc™, in a Phase 1 clinical trial.

Pittman PR, Reisler RB, Lindsey CY, Güereña F, Rivard R, Clizbe DP, Chambers M, Norris S, Smith LA.

Vaccine. 2015 Dec 16;33(51):7299-7306. doi: 10.1016/j.vaccine.2015.10.094. Epub 2015 Nov 3.

PMID:
26546259
7.

Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.

Pittman PR, Garman PM, Kim SH, Schmader TJ, Nieding WJ, Pike JG, Knight R, Johnston SC, Huggins JW, Kortepeter MG, Korman L, Ranadive M, Quinn X, Meyers MS.

Vaccine. 2015 Jun 12;33(26):2990-6. doi: 10.1016/j.vaccine.2015.04.062. Epub 2015 Apr 27.

PMID:
25930115
8.

Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.

Pittman PR, Cavicchia MA, Kingsbury JL, Johnson NA, Barrera-Oro JG, Schmader T, Korman L, Quinn X, Ranadive M.

Vaccine. 2014 Sep 3;32(39):5131-9. doi: 10.1016/j.vaccine.2014.03.076. Epub 2014 May 14.

PMID:
24837771
9.

Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.

Pugh C, Keasey S, Korman L, Pittman PR, Ulrich RG.

Clin Vaccine Immunol. 2014 Jun;21(6):877-85. doi: 10.1128/CVI.00035-14. Epub 2014 Apr 23.

10.

Transcriptional profiling of recall responses to Francisella live vaccine strain.

Paranavitana C, DaSilva L, Vladimirova A, Pittman PR, Velauthapillai M, Nikolich M.

Pathog Dis. 2014 Mar;70(2):141-52. doi: 10.1111/2049-632X.12113. Epub 2014 Jan 23.

PMID:
24453125
11.

Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.

Pittman PR, Fisher D, Quinn X, Schmader T, Barrera-Oro JG.

Vaccine. 2013 Oct 17;31(44):5009-14. doi: 10.1016/j.vaccine.2013.08.086. Epub 2013 Sep 8.

PMID:
24026013
12.

Quantitative assessment of anthrax vaccine immunogenicity using the dried blood spot matrix.

Schiffer JM, Maniatis P, Garza I, Steward-Clark E, Korman LT, Pittman PR, Mei JV, Quinn CP.

Biologicals. 2013 Mar;41(2):98-103. doi: 10.1016/j.biologicals.2012.11.003. Epub 2012 Dec 21.

PMID:
23266055
13.

Advances in development of countermeasures for potential biothreat agents.

Pittman PR, McKee KT Jr, Dembek ZF.

Adv Prev Med. 2012;2012:570246. doi: 10.1155/2012/570246. Epub 2012 Jul 16. No abstract available.

14.

Th17 cytokines in recall responses against Francisella tularensis in humans.

Paranavitana C, Zelazowska E, DaSilva L, Pittman PR, Nikolich M.

J Interferon Cytokine Res. 2010 Jul;30(7):471-6. doi: 10.1089/jir.2009.0108.

PMID:
20626289
15.

Immune interference after sequential alphavirus vaccine vaccinations.

Pittman PR, Liu CT, Cannon TL, Mangiafico JA, Gibbs PH.

Vaccine. 2009 Aug 6;27(36):4879-82. doi: 10.1016/j.vaccine.2009.02.090. Epub 2009 Mar 11.

PMID:
19576665
16.

Transcriptional profiling of Francisella tularensis infected peripheral blood mononuclear cells: a predictive tool for tularemia.

Paranavitana C, Pittman PR, Velauthapillai M, Zelazowska E, Dasilva L.

FEMS Immunol Med Microbiol. 2008 Oct;54(1):92-103. doi: 10.1111/j.1574-695X.2008.00456.x. Epub 2008 Aug 1.

17.

An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.

Hewetson JF, Little SF, Ivins BE, Johnson WM, Pittman PR, Brown JE, Norris SL, Nielsen CJ.

Vaccine. 2008 Aug 5;26(33):4262-6. doi: 10.1016/j.vaccine.2008.05.068. Epub 2008 Jun 12.

PMID:
18586363
18.

Transcriptome analysis of human immune responses following live vaccine strain (LVS) Francisella tularensis vaccination.

Fuller CL, Brittingham KC, Porter MW, Hepburn MJ, Petitt PL, Pittman PR, Bavari S.

Mol Immunol. 2007 May;44(12):3173-84. Epub 2007 Mar 8.

19.

Immunization to protect the US Armed Forces: heritage, current practice, and prospects.

Grabenstein JD, Pittman PR, Greenwood JT, Engler RJ.

Epidemiol Rev. 2006;28:3-26. Epub 2006 Jun 8. Review.

PMID:
16763072
20.

Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination.

Fuller CL, Brittingham KC, Hepburn MJ, Martin JW, Petitt PL, Pittman PR, Bavari S.

J Allergy Clin Immunol. 2006 May;117(5):1186-8. Epub 2006 Mar 31. No abstract available.

PMID:
16675351
21.

Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.

Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr.

Vaccine. 2006 Apr 24;24(17):3654-60. Epub 2006 Feb 9.

PMID:
16497418
22.

Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine.

Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, Norris SL, Anderson EL.

Vaccine. 2006 Apr 5;24(15):2843-9. Epub 2006 Jan 18.

PMID:
16494976
23.

Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.

Pittman PR, Leitman SF, Oro JG, Norris SL, Marano NM, Ranadive MV, Sink BS, McKee KT Jr.

Clin Diagn Lab Immunol. 2005 Jun;12(6):713-21.

24.
25.

Long-term health effects of repeated exposure to multiple vaccines.

Pittman PR, Coonan KM, Gibbs PH, Scott HM, Cannon TL, McKee KT Jr.

Vaccine. 2004 Dec 9;23(4):525-36.

PMID:
15530702
26.

Management guidelines for laboratory exposures to agents of bioterrorism.

Rusnak JM, Kortepeter MG, Hawley RJ, Boudreau E, Aldis J, Pittman PR.

J Occup Environ Med. 2004 Aug;46(8):791-800.

PMID:
15300131
27.

Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice.

Matyas GR, Rao M, Pittman PR, Burge R, Robbins IE, Wassef NM, Thivierge B, Alving CR.

J Immunol Methods. 2004 Mar;286(1-2):47-67.

PMID:
15087221
28.

Analysis of adverse events after anthrax immunization in US Army medical personnel.

Wasserman GM, Grabenstein JD, Pittman PR, Rubertone MV, Gibbs PP, Wang LZ, Golder LG.

J Occup Environ Med. 2003 Mar;45(3):222-33.

PMID:
12661179
29.
30.

Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.

Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT Jr, Friedlander AM, Sjogren MH.

Vaccine. 2002 May 15;20(16):2107-15.

PMID:
11972980
31.

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.

Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, Pace-Templeton JG, Myers R, Parker GW, Friedlander AM.

Vaccine. 2002 Jan 31;20(9-10):1412-20.

PMID:
11818160
32.

Anthrax vaccine: short-term safety experience in humans.

Pittman PR, Gibbs PH, Cannon TL, Friedlander AM.

Vaccine. 2001 Dec 12;20(5-6):972-8.

PMID:
11738765
33.

Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans.

Pittman PR, Mangiafico JA, Rossi CA, Cannon TL, Gibbs PH, Parker GW, Friedlander AM.

Vaccine. 2000 Sep 15;19(2-3):213-6.

PMID:
10930675
34.

An accelerated schedule for tick-borne encephalitis vaccine: the American Military experience in Bosnia.

Craig SC, Pittman PR, Lewis TE, Rossi CA, Henchal EA, Kuschner RA, Martinez C, Kohlhase KF, Cuthie JC, Welch GE, Sanchez JL.

Am J Trop Med Hyg. 1999 Dec;61(6):874-8.

PMID:
10674662
35.

Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax.

Friedlander AM, Pittman PR, Parker GW.

JAMA. 1999 Dec 8;282(22):2104-6. No abstract available.

PMID:
10591317
36.

Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.

Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, Gibbs PH, Peters CJ.

Vaccine. 1999 Aug 20;18(1-2):181-9.

PMID:
10501248
37.

Immunologic interference from sequential administration of live attenuated alphavirus vaccines.

McClain DJ, Pittman PR, Ramsburg HH, Nelson GO, Rossi CA, Mangiafico JA, Schmaljohn AL, Malinoski FJ.

J Infect Dis. 1998 Mar;177(3):634-41.

PMID:
9498442
38.
39.

Light-dependent inhibition of photophosphorylation by N-ethylmaleimide.

McCarty RE, Pittman PR, Tsuchiya Y.

J Biol Chem. 1972 May 25;247(10):3048-51. No abstract available.

Supplemental Content

Loading ...
Support Center